{
  "AuthorID": "Patrickha",
  "AuthorURL": "https://www.cancercompass.comhttps://www.cancercompass.com/profile/Patrickha",
  "Posts": [{
    "AuthorID": "Patrickha",
    "AuthorURL": "https://www.cancercompass.comhttps://www.cancercompass.com/profile/Patrickha",
    "Content": "Toremifene (Fareston) \u2013 this SERM is approved for treating metastatic breast cancer Fulvestrant (Faslodex) \u2013 this medication blocks estrogen receptor cells throughout the body and is given by injection to women with advanced stages of breast cancer that do not respond to tamoxifen or toremifene Aromatase inhibitors (AI\u2019s) \u2013anastrozole (Arimidex), letrozole (Femara), and exemestane (Aromasin) stop estrogen production in fatty tissues in post-menopausal women or those who have been treated with luteinizing hormone-releasing hormone analogs Source: https://goo.gl/uJtD4g",
    "MessageIndex": 0,
    "PostDate": "11/01/2016",
    "ThreadURL": "https://www.cancercompass.com/message-board/message/all,89086,0.htm",
    "Title": "How to reduce the risk of breast cancer from hormone therapy"
  }]
}